摘要:
The present invention relates to the use of myeloid cell biomarkers for the differential diagnosis, prognosis, and monitoring of renal cell carcinoma (RCC) or colorectal cancer (CRC). The present invention furthermore relates to monitoring the effect of a treatment against renal cell carcinoma (RCC) or colorectal cancer (CRC), and establishing a prognosis of the outcome of the treatment of renal cell carcinoma (RCC) or colorectal cancer (CRC). The present invention furthermore relates to panels of cellular biomarkers for use in the above methods, in particular multicolor panels for measuring said biomarkers.
摘要:
The invention involves the identification of an isolated nucleic acid molecule which encodes a tumor rejection antigen. Various uses of this nucleic acid molecule and the protein it encodes are discussed.
摘要:
The invention involves the identification of an isolated nucleic acid molecule which encodes a tumor rejection antigen. Various uses of this nucleic acid molecule and the protein it encodes are discussed.
摘要:
The invention relates to isolated cytolytic T cells which recognize complexes of HLA-B35 molecules and the peptide defined by SEQ ID NO: 2, as well as methods for identifying HLA-B35 positive cells. The method involves contacting the cytolytic T cells to a sample, and determining activity of these cytolytic T cells.
摘要翻译:本发明涉及识别HLA-B35分子和由SEQ ID NO:2定义的肽的复合物的分离的溶细胞T细胞以及鉴定HLA-B35阳性细胞的方法。 该方法包括将溶细胞T细胞接触样品,并测定这些溶细胞T细胞的活性。
摘要:
A population of myeloid-derived suppressor cells and the culture procedure to obtain these in vitro starting with bone marrow cells of mice, other animals and human beings, in the presence of specific cytokine combinations used to determine concentrations, is provided.